Home

Boundless Bio to Participate at Two Upcoming Investor Conferences

Boundless Bio, a next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) in oncogene amplified cancers, today announced that its Chief Executive Officer, Zachary Hornby, will participate in a presentation and fireside chat at upcoming investor conferences:

Piper Sandler 34th Annual Healthcare Conference

Format: Presentation

Date: Tuesday, November 29, 2022

Time: 8:30 AM – 8:50 AM ET

5th Annual Evercore ISI HealthCONx Conference

Format: Fireside chat (virtual)

Date: Tuesday, November 29, 2022

Time: 1:50 PM – 2:10 PM ET

About Boundless Bio

Boundless Bio is a next-generation precision oncology company dedicated to the discovery and development of a new class of drugs targeting a novel area of cancer biology, extrachromosomal DNA (ecDNA), to deliver transformative therapies to patients with oncogene amplified cancers.

For more information, visit www.boundlessbio.com.

Follow us on LinkedIn and Twitter.

Contacts